PR85515

LONDON, Sept. 10, 2020 /PRNewswire=KYODO JBN/ --

Haoma Medica announced today that it will present three scientific posters on

NaQuinate at the American Society for Bone and Mineral Research (ASBMR) 2020

Annual Meeting, which this year takes place as a virtual event from the 11-15

September. NaQuinate, a naphthoquinone carboxylic acid, is being developed as a

novel orally administered therapeutic for osteoporosis. "Haoma Medica is

dedicated to investigating new ways to treat osteoporosis and maintain healthy

aging and we look forward to sharing new pre-clinical data for NaQuinate at

this key meeting with bone health experts" said Prof Stephen Hodges, Haoma

Medica's Chief Scientific Officer.

Haoma Medica will present the following abstracts at ASBMR:

- NaQuinate: A Drug that Selectively Synergizes with Mechanical Loading Stimuli

In Vivo to Generate Greater Cortical Bone Mass and Architectural Modifications

Plenary Poster Presentation Number: P-300

- NaQuinate Protects Against Ovariectomy-Induced Changes in Cortical Bone Mass

and Architecture Through a Regionally Targeted Mechanism

Poster Presentation Number: P-734

- NaQuinate, a Vitamin K Catabolite, is Found in Blood After Oral Vitamin K

Administration and it can Reduce Osteoclast Activity Without Effecting

Osteoclast Number in Culture

Poster Presentation Number: P-339

About Osteoporosis

Osteoporosis is a silent disease often not presenting with any signs or

symptoms until a fracture occurs. It thus remains an underdiagnosed and

undertreated disease.

Osteoporosis results in bone loss and changes in bone quality that occurs

through the normal aging process leading to fragile bones. Fragile bones lead

to fractures, which progresses into a downward spiral of disability, loss of

independence and increased mortality with considerable social and economic

burden. Fragility fractures are therefore a major obstacle to healthy aging.

Worldwide there is a fragility fracture every 3 seconds.

According to the National Osteoporosis Foundation about 54 million Americans

have osteoporosis with studies suggesting one in two women and one in four men

aged 50 and older will have a fragility fracture (from low level impact often

occurring from a minor bump/fall from standing height) within their lifespan.

About Haoma Medica

Haoma Medica Ltd is a clinical-stage biotechnology company focused on the

development of therapeutics to maintain bone and vascular health.

For more information, please visit www.haomamedica.com

Logo - https://mma.prnewswire.com/media/1251548/Haoma_Medica_Logo.jpg 

Investor Relations Contact

Name: Carmen Greco                                                

e-mail: carmen.greco@haomamedica.com          

Phone: +44 (0)207 629 1954                                        

Source - Haoma Medica Ltd.